Clovis Oncology

Bob Azelby to join Cardinal Health Board of Directors

Retrieved on: 
Wednesday, February 28, 2024
Amgen, Cardinal Health, MBA, ADC, Juno Therapeutics, University, Therapy, Organization, CAH, Harvard Business School, Religious studies, Clovis Oncology, Lundbeck Seattle Biopharmaceuticals, Management

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.

Key Points: 
  • DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.
  • Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.
  • Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics.
  • "Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health.

Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups

Retrieved on: 
Wednesday, December 13, 2023
Professional Services, Health, Start-Up, Other Science, Finance, Science, Biotechnology, EOS, Harvard University, Acquisition, Luisa Seghezzi, Therapy, Acceleration, Lineage Cell Therapeutics, Ewing Marion Kauffman Foundation, Systems biology, Sofinnova, Partner, Growth, Doctor of Philosophy, Clovis Oncology, Pharmaceutical industry, Management

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita , an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.

Key Points: 
  • Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita , an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.
  • The strategy builds upon Sofinnova’s established track record of nurturing innovative ventures within the healthcare and sustainability sectors.
  • Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “With Sofinnova Biovelocita, we are doubling down on our commitment to innovation and company creation in the life sciences.
  • Zhizhong (Joel) Yao , Partner, a former Principal in the Sofinnova Capital Strategy, and a Kauffman Fellow, instrumental in the launch of several biotech start-ups.

Antiva Biosciences Strengthens Leadership with Key New Appointments

Retrieved on: 
Thursday, October 19, 2023
Human papillomavirus infection, Astex Pharmaceuticals, KAI, Project management, OB, Health, CIN, Therapy, Pharmacovigilance, FACOG, HPV, CMC, Acquisition, BRCA, Roivant Sciences, Division of Program Coordination, Planning, and Strategic Initiatives, Amgen, Clovis Oncology, Cancer, CMO, Chemistry, Apoptosis, Patient, Diagnosis, Management, Pharmaceutical industry, Medical device, Tuba Mirum (Paus), EU

REDWOOD CITY, Calif., Oct. 18, 2023 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by human papilloma virus (HPV), today announced several key new appointments designed to strengthen the company's leadership as it continues to advance its lead development candidate, ABI-2280. The company has added Elaine Chien, M.D., FACOG, as chief medical officer, Susan Wilson, Ph.D., as vice president of project management and strategic initiatives, and Rajashree Joshi-Hangal, Ph.D., as vice president of technical operations. Collectively, these individuals bring Antiva significant industry experience in areas directly related to the company's ongoing work in developing innovative treatments for diseases caused by HPV infection.

Key Points: 
  • Collectively, these individuals bring Antiva significant industry experience in areas directly related to the company's ongoing work in developing innovative treatments for diseases caused by HPV infection.
  • "With the closing of our Series E financing earlier this year, Antiva entered an important new phase as we work to advance ABI-2280 into key efficacy studies across multiple indications.
  • Antiva is currently working to advance ABI-2280 into key efficacy studies.
  • She has also held positions of increasing managerial responsibilities in both technical and regulatory CMC areas  at Astex Pharmaceuticals.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Peptone Expands Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 28, 2023
University of Oxford, DNA, Laboratory, Specialization, Drug development, University, Therapy, Senior, Intrinsically disordered proteins, Chiron Corporation, Drug discovery, CSO, Head, Abbott Laboratories, Nuffield Department of Population Health, Gritstone bio, Inflammation, Antibody, Doctor of Philosophy, AstraZeneca, Drug design, Internally displaced person, Messenger, McKinsey & Company, Neuroscience, Cryogenic electron microscopy, Protein, MD, Biophysics, Chairperson, Jazz Pharmaceuticals, Biology, Growth, Imperial College London, Rucaparib, Exosome, DNA methylation, Research, Clovis Oncology, Health, A-DNA, SVP, PARP, Somerville College, Oxford, Disease, Management, Pharmaceutical industry, Medicine, Peptide, Immunology

LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors. Patrik Foerch, PhD, has been appointed Chief Scientific Officer; David Lowe, PhD, joins as Senior Vice President of Protein Therapeutics; and Benjamin Owens, PhD, previously Chief Strategy Officer, has transitioned to the role of Chief Business Officer and will join Peptone's Board of Directors as Executive Director. Andrew Allen, MD, PhD, co-founder, President and CEO of Gritstone bio, has been appointed Board Chair.

Key Points: 
  • LONDON and BELLINZONA, Switzerland, Sept. 28, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), today announced the appointment of key leaders to its Executive Management Team and Board of Directors.
  • "I'm excited to join this incredible team to chart new territory with potential to open therapeutic opportunities across a broad range of diseases."
  • Prior to joining Peptone, he served as Vice President of Research at Evox Therapeutics, a company focused on the development of exosomes as therapeutics.
  • He has also held clinical development leadership positions at Chiron Corporation and Abbott Laboratories and worked at McKinsey & Company.

Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

Retrieved on: 
Thursday, April 13, 2023
Amgen, IPO, University, Nephrology, Sale, Acquisition, Patient, Religious studies, Kidney, Harvard Business School, Juno Therapeutics, Clovis Oncology, Therapy, Pharmaceutical industry, Lundbeck, Economics, Chinook

SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors.

Key Points: 
  • SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors.
  • Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook.
  • “We are thrilled to welcome Bob to Chinook’s board of directors as we advance our pipeline through key milestones in 2023 and beyond,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics.
  • “I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialization.”

Delisting of Securities of Tuscan Holdings Corp. II; Clovis Oncology, Inc.; ZyVersa Therapeutics, Inc.; Otonomy, Inc., and Forward Pharma A/S from The Nasdaq Stock Market

Retrieved on: 
Wednesday, December 28, 2022
Therapy, Bangladesh Securities and Exchange Commission, News, Security (finance), Clovis Oncology, Delisting, American depositary receipt, PAETEC Holding Corp., Online shopping

Tuscan Holdings Corp. II’s securities were suspended on November 21, 2022, and have not traded on Nasdaq since that time.

Key Points: 
  • Tuscan Holdings Corp. II’s securities were suspended on November 21, 2022, and have not traded on Nasdaq since that time.
  • Nasdaq also announced today that it will delist the common stock of Clovis Oncology, Inc. Clovis Oncology, Inc.’s securities were suspended on December 21, 2022, and have not traded on Nasdaq since that time.
  • Forward Pharma A/S’s securities were suspended on December 28, 2022, and have not traded on Nasdaq since that time.
  • Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series .

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Pharmaceutical, Health, Oncology, LLP, Willkie Farr & Gallagher, Novartis, Clovis Oncology, Bankruptcy, United States bankruptcy court, Hart–Scott–Rodino Antitrust Improvements Act, AlixPartners, Sale, DIP, Chapter 11, Title 11, United States Code, Bankruptcy Code, Debtor, Security (finance)

In order to provide necessary funding during the Chapter 11 proceeding, Clovis has received a commitment of up to $75 million in a multi-draw DIP financing facility.

Key Points: 
  • In order to provide necessary funding during the Chapter 11 proceeding, Clovis has received a commitment of up to $75 million in a multi-draw DIP financing facility.
  • Clovis is also actively engaged in discussions with a number of interested parties with respect to a potential sale of one or more of its other assets.
  • Clovis is represented by Willkie Farr & Gallagher LLP as counsel, AlixPartners LLP as restructuring advisor and Perella Weinberg Partners L.P. as restructuring investment banker.
  • Additional information about the Chapter 11 case, including access to Bankruptcy Court documents, is available online at https://cases.ra.kroll.com/Clovis .

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Colon, Therapy, Neoplasm, EMA, Hyponatremia, NASDAQ, Antibody, Lymphocytopenia, SD, University, Abdominal distension, Primary sclerosing cholangitis, Association, Pseudomyxoma peritonei, CEO, Toxic leukoencephalopathy, University of California, San Francisco, Mesothelioma, UCSF, Database administrator, Population, Data, HIV disease progression rates, Cancer, Private Securities Litigation Reform Act, TRT, Department, Literature, Peptide, FDA, Isotope, RECIST, FAP, EANM, Kidney, Research, Security (finance), Cell, Trial of the century, Gallium, U.S. Securities and Exchange Commission, Radiation, Clovis Oncology, View, Sarcoma, Patient, Radiology, Gallbladder cancer, Drug discovery, Molecular Therapy, Toxicity, Safety, Biomedicine, Pharmaceutical industry, Medical imaging, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • The LuMIERE trial is the first prospective trial of a FAP peptide targeted radionuclide therapy and is currently in the dose escalation phase.
  • Updated results from the Phase 1 portion of the ongoing Phase 1/2 LuMIERE study found treatment-emergent adverse events (TEAEs) were mostly Grade 1 and 2 across cohorts.

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Isotope, Half-life, Peptide, Nuclear pharmacy, Database administrator, Therapy, Safety, Radiation, Molecular imaging, Clovis Oncology, Sarcoma, FDA, FAP, SNMMI, Neoplasm, Antibody, Company, Population, Cancer, Private Securities Litigation Reform Act, Isotopia Festival, EANM, U.S. Securities and Exchange Commission, Program, Patient, Colon, CEO, Oncology, Gallium, Cell, Fibroblast, Radionuclide, NCT, NASDAQ, CAFS, Research, Security (finance), Congress, Mesothelioma, BD, GMP, EMA, View, Drug discovery, TRT, Pharmaceutical industry, Medical imaging

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement further secures our ability to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.
  • Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security, said Keren Moshkoviz, Deputy CEO and BD at Isotopia.